Impact of stopping therapy during the SARS-CoV-2 pandemic in persons with lymphoma
- PDF / 645,603 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 8 Downloads / 157 Views
ORIGINAL ARTICLE – CLINICAL ONCOLOGY
Impact of stopping therapy during the SARS‑CoV‑2 pandemic in persons with lymphoma Shenmiao Yang1 · Dong Dong2 · Hongfei Gu3 · Robert Peter Gale4 · Jun Ma5 · Xiaojun Huang1 Received: 17 September 2020 / Accepted: 10 October 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Introduction The severe acute respiratory syndrome-2 (SARS-CoV-2) pandemic disrupted medical care for persons with cancer including those with lymphoma. Many professional societies recommend postponing, decreasing, or stopping anticancer therapy in selected persons during the pandemic. Although seemingly sensible, these recommendations are not evidence-based and their impact on anxiety and health-related quality-of-life (HRQoL) is unknown. Methods We surveyed 2532 subjects including 1060 persons with lymphoma, 948 caregivers, and 524 normals using a purposed-designed questionnaire on a patient organization website. Respondents also completed the Zung Self-Rating Anxiety and patient respondents, the EORTC QLQ-C30 instruments to quantify anxiety, and HRQoL. We also evaluated caregiver support and an online education programme of the Chinese Society of Clinical Oncology (CSCO). Data of HRQoL from a 2019 pre-pandemic online survey of 1106 persons with lymphoma were a control. Results 33% (95% confidence interval [CI] 30, 36%) of lymphoma patients and 31% (28, 34%) of caregivers but only 21% (17, 24%) of normals had any level of anxiety (both pair-wise P 69), 4%, 7%, and 6% (P = 0.22). We evaluated co-variates associated with anxiety in respondents (Table 3). No SARS-CoV-2 infection (Hazard Ratio [HR] = 0.15 (0.041, 0.53; P = 0.003), being a normal versus a patient or caregiver (HR = 0.53 [0.42, 0.68]; P
Data Loading...
